Company / Free Cash Flow per Share
Esperion Therapeutics, Inc. Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$0.06
FY2025
5-year range
-$9.74 / -$0.06
FY2021-FY2025
Trend
+50.8%
vs FY2024
Sector context
#70 of 192
Health Care
What the data says
At $-0.06, Esperion Therapeutics, Inc.'s free cash flow per share ranks #70 of 192 in the Health Care sector. Free Cash Flow per Share has increased for 4 consecutive years, from $-9.74 in FY2021 to $-0.06 in FY2025.
Based on SEC 10-K filings.
-0.06 in FY2025.
Improved from $-1.31 to $-0.06 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#70 of 192 in Health CareTop 36% of 192This company -$0.06 Sector average -$19.84
▼
+99.7% above sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s free cash flow per share has grown for 4 consecutive years.
- In FY2025, free cash flow per share increased 50.8% year-over-year.
- Ranks #70 out of 192 companies in the Health Care sector.
- Lowest free cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.06 | +50.8% |
| FY2024 | -$0.13 | +90.3% |
| FY2023 | -$1.31 | +50.1% |
| FY2022 | -$2.63 | +73.0% |
| FY2021 | -$9.74 | -211.2% |
| FY2020 | -$3.13 | -17.7% |
| FY2019 | -$2.66 | +52.2% |
| FY2018 | -$5.56 | -1.4% |
| FY2017 | -$5.49 | -158.7% |
| FY2016 | -$2.12 | -21.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026